TDP 43 condensate modulator - Dewpoint Therapeutics
Alternative Names: TDP-43 condensate modulatorLatest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator Dewpoint Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action TDP-43 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 01 Dec 2024 Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation enters into a strategic research collaboration agreement to advance small molecule condensate modulator for Amyotrophic lateral sclerosis
- 07 Jan 2024 Dewpoint Therapeutics has patents pending for novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS)
- 07 Jan 2024 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) (Dewpoint Therapeutics pipeline, January 2024)